Protocol Ledger

NCT03395639 · Phase III · COMPLETED

Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

Interventional Phase III clinical trial protocol NCT03395639 sponsored by Daiichi Sankyo in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-15 Enrollment: 168 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03395639
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)168 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03395639
Protocol FieldVerified Registry Value
NCT IdentifierNCT03395639
Consolidated Lead SponsorDaiichi Sankyo
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment168 participants (ACTUAL)
Registered Start Date2018-05-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI